Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Incremental Cost of Prematurity by Week of Gestational Age.

Walsh EM, Li SX, Black LK, Kuzniewicz M.

AJP Rep. 2019 Jan;9(1):e76-e83. doi: 10.1055/s-0039-1683934. Epub 2019 Mar 19.

2.

Increased risk of morbidities and health-care utilisation in children born following preterm labour compared with full-term labour: A population-based study.

Houben E, Smits E, Pimenta JM, Black LK, Bezemer ID, Penning-van Beest FJ.

J Paediatr Child Health. 2019 Apr;55(4):446-453. doi: 10.1111/jpc.14225. Epub 2018 Oct 4.

PMID:
30288825
3.

Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.

Roehrborn CG, Wilson TH, Black LK.

J Urol. 2012 May;187(5):1732-8. doi: 10.1016/j.juro.2011.12.083. Epub 2012 Mar 15.

PMID:
22425127
4.

Lifetime economic burden of prostate cancer.

Stokes ME, Ishak J, Proskorovsky I, Black LK, Huang Y.

BMC Health Serv Res. 2011 Dec 28;11:349. doi: 10.1186/1472-6963-11-349.

5.

Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.

Bjerklund Johansen TE, Baker TM, Black LK.

BJU Int. 2012 Mar;109(5):731-8. doi: 10.1111/j.1464-410X.2011.10511.x. Epub 2011 Sep 20.

6.

The economic burden of prostate cancer.

Roehrborn CG, Black LK.

BJU Int. 2011 Sep;108(6):806-13. doi: 10.1111/j.1464-410X.2011.10365.x. Review.

7.

Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.

Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL.

Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15. doi: 10.2165/11592200-000000000-00000.

PMID:
21875161
8.

Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.

Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW.

Pharmacoeconomics. 2010;28(6):489-505. doi: 10.2165/11531780-000000000-00000.

PMID:
20196623
9.

Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.

Fourcade RO, Benedict A, Black LK, Stokes ME, Alcaraz A, Castro R.

BJU Int. 2010 Jan;105(1):49-56. doi: 10.1111/j.1464-410X.2009.08716.x.

10.

Incontinence related to management of benign prostatic hypertrophy.

Han E, Black LK, Lavelle JP.

Am J Geriatr Pharmacother. 2007 Dec;5(4):324-34. doi: 10.1016/j.amjopharm.2007.12.003.

PMID:
18179990
11.

Structure-function relationships of a novel bacterial toxin, hemolysin E. The role of alpha G.

Atkins A, Wyborn NR, Wallace AJ, Stillman TJ, Black LK, Fielding AB, Hisakado M, Artymiuk PJ, Green J.

J Biol Chem. 2000 Dec 29;275(52):41150-5.

12.

Headache medication-use among primary care headache patients in a health maintenance organization.

Von Korff M, Black LK, Saunders K, Galer BS.

Cephalalgia. 1999 Jul;19(6):575-80; discussion 541-2.

PMID:
10448544
13.

IHF- and RpoN-dependent regulation of hydrogenase expression in Bradyrhizobium japonicum.

Black LK, Maier RJ.

Mol Microbiol. 1995 May;16(3):405-13.

PMID:
7565102
15.
16.

Hydrogen-sulfur autotrophy in the hyperthermophilic archaebacterium, Pyrodictium brockii.

Pihl TD, Schicho RN, Black LK, Schulman BA, Maier RJ, Kelly RM.

Biotechnol Genet Eng Rev. 1990;8:345-77. Review. No abstract available.

PMID:
2128798

Supplemental Content

Loading ...
Support Center